Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Summary
The purpose of this phase Ib/II study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.
General Information
NCT#: NCT02807844
Study ID: CMCS110Z2102
Trial Phase: Phase I/II
Trial Sponsor: Novartis Pharmaceuticals
Therapies Used in This Trial: Spartalizumab, MCS110